A leading provider of clinical-grade precision genomics information to researchers, clinicians, pharmaceutical companies and the US Department of Veteran Affairs (VA), Personalis is using its advanced capabilities in the generation and interpretation of sequencing data to analyse whole genomes, exomes and transcriptomes. The company is particularly focused on the application of its ACE ImmunoID™ platform in immuno-oncology, and on whole genome sequencing for the VA's Million Veterans Program. Company recently raised $155m in a Nasdaq IPO with nasdaq ticker: PSNL